ADVERSE EVENTS RELATED TO SARS-COV-2 VACCINE IN A NATIONWIDE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

BACKGROUND: There is limited data on the safety profile of SARS-CoV-2 vaccine among patients taking immunosuppressive medications. Our aim was to evaluate the adverse events related to the vaccines in a nationwide cohort of inflammatory bowel disease (IBD) patients on diverse immunosuppressive medications. METHODS: This was a retrospective cohort study using data from the Veterans Health Administration (VHA). The primary outcome was any adverse event of special interest, (cerebrovascular accident, venous thromboembolism, acute myocardial infarction, Bell’s palsy) within 90 days of vaccination. RESULTS: A total of 17,201 patients were included. 12,351 (71.8%) received at least 1 vaccine dose. The most common adverse events were acute myocardial infarction and venous thromboembolism. In inverse probability treatment weighting-adjusted logistic regression, full vaccination was not significantly associated with increased adverse events through 90 days, relative to unvaccinated patients. CONCLUSION: Full SARS-CoV-2 vaccination was not associated with an increased rate of key adverse events relative to unvaccinated individuals among IBD patients